Drug Profile
Research programme: siRNA hearing loss therapies - Alnylam Pharmaceuticals
Latest Information Update: 16 May 2014
Price :
$50
*
At a glance
- Originator Sirna Therapeutics
- Developer Massachusetts General Hospital
- Class
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Sensorineural hearing loss